Evidence map›Paper›PMID 31977161›Full record

ArticleFEBS open bio2020

CD140b and CD73 are markers for human induced pluripotent stem cell-derived erythropoietin-producing cells.

Shogo Nishimoto, Tomohiro Mizuno, Kazuo Takahashi, Fumihiko Nagano, Yukio Yuzawa, Akira Nishiyama, Kenji Osafune, Hirofumi Hitomi, Tadashi Nagamatsu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in FEBS open bio, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.1field-weighted citation impact, top 58% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Erythropoietin levels in geriatric anemia.Journal of family medicine and primary care · 2024
    Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 2 countries.

Shogo NishimotoDepartment of Analytical Pharmacology, Meijo University, Nagoya, Japan.
Tomohiro MizunoDepartment of Analytical Pharmacology, Meijo University, Nagoya, Japan.ORCID 0000-0001-8203-392X
Kazuo TakahashiDepartment of Nephrology, School of Medicine, Fujita Health University, Toyoake, Japan.
Fumihiko NaganoDepartment of Analytical Pharmacology, Meijo University, Nagoya, Japan.
Yukio YuzawaDepartment of Nephrology, School of Medicine, Fujita Health University, Toyoake, Japan.
Akira NishiyamaDepartment of Pharmacology, Faculty of Medicine, Kagawa University, Japan.
Kenji OsafuneDepartment of Cell Growth and Differentiation, Center for iPS Cell Research and Application (CiRA), Kyoto University, Japan.
Hirofumi HitomiDepartment of iPS Stem Cell Regenerative Medicine, Kansai Medical University, Osaka, Japan.
Tadashi NagamatsuDepartment of Analytical Pharmacology, Meijo University, Nagoya, Japan.
Meijo University · JPFujita Health University · JPKagawa University · JPKansai Medical University · JPKyoto University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Renal anemia in chronic kidney disease is treated with recombinant human erythropoietin (rhEPO). However, some patients with anemia do not respond well to rhEPO, emphasizing the need for a more biocompatible EPO. Differentiation protocols for hepatic lineages have been modified to enable production from human induced pluripotent stem cell (hiPSC)-derived EPO-producing cells (EPO cells). However, markers for hiPSC-EPO cells are lacking, making it difficult to purify hiPSC-EPO cells and therefore to optimize EPO production and cell counts for transplantation. To address these issues, we investigated whether CD140b and CD73 could be used as markers for hiPSC-EPO cells. We measured the expression of EPO, CD140b, and CD73 in hiPSC-EPO cells and the EPO concentration in the cell supernatant by immunohistochemistry and enzyme-linked immunosorbent assays on culture day 13, revealing that expression levels of CD140b and CD73 are correlated with the level of EPO. In addition, rates of CD140b

Indexed as

5'-NucleotidaseAnemiaBiomarkersCell DifferentiationErythroid Precursor CellsErythropoietinGPI-Linked ProteinsHumansInduced Pluripotent Stem CellsReceptor, Platelet-Derived Growth Factor betaRenal Insufficiency, Chronic5'-NucleotidaseBiomarkersEPO protein, humanErythropoietinGPI-Linked ProteinsNT5E protein, humanPDGFRB protein, humanReceptor, Platelet-Derived Growth Factor betaCD140bCD73chronic kidney diseaseerythropoietinhuman induced pluripotent stem cells

Identifiers

PMID31977161
PMCPMC7050240
OpenAlexW3001094371

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.